The global radiopharmaceuticals market is projected to reach $12.8B–$21.8B by 2033–2036, driven by cancer therapy demand. Oncology accounts for over 50% of applications, Technetium-99m dominates radioisotopes, and Asia-Pacific leads growth.
Olema Pharmaceuticals appointed Prakash Raman, Ph.D., to its board of directors. The company said the oncology deal veteran joins as Olema advances palazestrant and OP-3136 while remaining loss-making.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06783348 |
Radiopharmaceutical Treatment of Advanced Kidney Cancer |
RECRUITING | PHASE2 |
| NCT04529044 |
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer |
RECRUITING | PHASE2 |
| NCT03872778 |
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake |
COMPLETED | PHASE1/PHASE2 |
